Prognostic factors analysis in 335 ARL lymphoma patients treated by CHOP (n = 204) or Ld-CHOP (n = 131)
. | CHOP/Ld-CHOP population . | . | Before HAART . | . | After HAART . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Prognostic factors . | 3-y OS . | P . | 3-y OS . | P . | 3-y OS . | P . | |||
| aaIPI score, no. (95% CI) | <.001* | <.001 | <.001* | ||||||
| 0-1 | 37 (30, 45) | 27 (18, 35) | 54 (42, 66) | ||||||
| 2-3 | 16 (8, 23) | 12 (3, 20) | 22 (8, 35) | ||||||
| HIV score, no. (95% CI) | <.001* | <.001* | .13 | ||||||
| 0 | 46 (37, 56) | 39 (27, 51) | 56 (41, 71) | ||||||
| 1 | 26 (19, 33) | 19 (11, 27) | 50 (35, 58) | ||||||
| 2-3 | 10 (2, 20) | 2 (0, 7) | 34 (23, 45) | ||||||
| Straus score, no. (95% CI) | <.001 | <.001 | .06 | ||||||
| 0-1 | 44 (32, 56) | 36 (22, 50) | 61 (41, 82) | ||||||
| 2 | 28 (19, 36) | 20 (10, 19) | 40 (25, 54) | ||||||
| 3-4 | 19 (11, 27) | 9 (2, 17) | 34 (19, 51) | ||||||
| NHL subtype, no. (95% CI) | .009* | .21 | .10 | ||||||
| Diffuse large B-cell | 38 (32, 44) | 29 (22, 34) | 49 (41, 57) | ||||||
| Immunoblastic | 22 (14, 30) | 17 (7, 27) | 33 (23, 43) | ||||||
| Burkitt | 28 (21, 36) | 24 (14, 44) | 32 (22, 42) | ||||||
| HAART era, no. (95% CI) | <.001* | NA | NA | ||||||
| Before HAART | 22 (16, 28) | NA | NA | ||||||
| After HAART | 42 (34, 51) | NA | NA | ||||||
. | CHOP/Ld-CHOP population . | . | Before HAART . | . | After HAART . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Prognostic factors . | 3-y OS . | P . | 3-y OS . | P . | 3-y OS . | P . | |||
| aaIPI score, no. (95% CI) | <.001* | <.001 | <.001* | ||||||
| 0-1 | 37 (30, 45) | 27 (18, 35) | 54 (42, 66) | ||||||
| 2-3 | 16 (8, 23) | 12 (3, 20) | 22 (8, 35) | ||||||
| HIV score, no. (95% CI) | <.001* | <.001* | .13 | ||||||
| 0 | 46 (37, 56) | 39 (27, 51) | 56 (41, 71) | ||||||
| 1 | 26 (19, 33) | 19 (11, 27) | 50 (35, 58) | ||||||
| 2-3 | 10 (2, 20) | 2 (0, 7) | 34 (23, 45) | ||||||
| Straus score, no. (95% CI) | <.001 | <.001 | .06 | ||||||
| 0-1 | 44 (32, 56) | 36 (22, 50) | 61 (41, 82) | ||||||
| 2 | 28 (19, 36) | 20 (10, 19) | 40 (25, 54) | ||||||
| 3-4 | 19 (11, 27) | 9 (2, 17) | 34 (19, 51) | ||||||
| NHL subtype, no. (95% CI) | .009* | .21 | .10 | ||||||
| Diffuse large B-cell | 38 (32, 44) | 29 (22, 34) | 49 (41, 57) | ||||||
| Immunoblastic | 22 (14, 30) | 17 (7, 27) | 33 (23, 43) | ||||||
| Burkitt | 28 (21, 36) | 24 (14, 44) | 32 (22, 42) | ||||||
| HAART era, no. (95% CI) | <.001* | NA | NA | ||||||
| Before HAART | 22 (16, 28) | NA | NA | ||||||
| After HAART | 42 (34, 51) | NA | NA | ||||||
For CHOP/Ld-CHOP population, n = 335; for pre-HAART patients, n = 199; for post-HAART patients, n = 136.
NA indicates not applicable.
P ≤ .05 in multivariate analysis.